The effect of high flow nasal oxygen therapy in intensive care units: a systematic review and meta-analysis

Expert Rev Respir Med. 2021 Oct;15(10):1335-1345. doi: 10.1080/17476348.2021.1937131. Epub 2021 Jun 21.

Abstract

Background: High flow nasal oxygen (HFNO) therapy has been widely used in intensive care units (ICU); however, its efficacy remains inconclusive. This systematic review and meta-analysis aimed to compare the efficacy of HFNO therapy with th at of alternative noninvasive oxygen therapies such as conventional oxygen therapy (COT) and noninvasive ventilation (NIV) in ICU.

Methods: A Pubmed, Embase, Web of Science, Cochrane Library database search was performed in March 2020. Results: The meta-analysis ultimately included 17 clinical studies. Compared with the overall effect of COT and NIV, HFNO was associated with a low incidence of pneumonia (95% CI: 0.6-0.99, P = 0.04) and improvement in lowest pulse oxygen saturation (SpO₂) during oxygenation (95% CI: 0.02-1.61; P = 0.04). However, no differences were detected in the following outcomes: length of ICU stay, the rate of intubation or reintubation, mortality at day 28, hospital mortality, and SpO₂ at the end of oxygen therapy (all P > 0.05).

Conclusions: In adult patients in ICU, HFNO may improve oxygenation and decrease pneumonia rate without affecting the length of ICU stay, intubation or reintubation rate, mortality, and SpO₂ at the end of oxygen therapy.

Keywords: High flow nasal cannula; intensive care unit; length of stay; meta-analysis; oxygen inhalation therapy; pneumonia.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Adult
  • Hospital Mortality
  • Humans
  • Intensive Care Units
  • Noninvasive Ventilation* / adverse effects
  • Oxygen Inhalation Therapy
  • Oxygen*

Substances

  • Oxygen